Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter (PREFACE)

This study has been terminated.
(Difficulty to include patients)
Sponsor:
Collaborators:
Sanofi
Ministry of Health, France
LivaNova
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT00736294
First received: August 14, 2008
Last updated: July 27, 2015
Last verified: July 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)